In Massachusetts, Lilly Asia Ventures, Trustbridge Partners, and Jiangsu Simcere Pharmaceutical gave Veritas Genetics $30 million in Series B funding. Veritas Genetics focuses on genome sequencing and genetic screening tests, mostly related to cancer and reproductive health. Veritas was the first company to offer genetic sequencing for under $1,000, making it a realistic prospect for more people. Mirza Cifric, founder and CEO of Veritas Genetics, told PR Newswire, “With a $999 genome, we are at the tipping point of a transformation in healthcare where the genome is going to be at the center of many decisions we make about our health and quality of life, throughout our lives.” This latest funding will go towards global expansion of operations and hospital and researcher partnerships. They welcomed three new executives to their team to help with the expansion, Tim Smith as Chief Operating Officer, Rodrigo Martinez as Chief Marketing and Design Officer, and Doug Flood as Chief Commercial Officer.
Latest article
Absolut Vodka inks new partnership in biodegradable bottle pursuit
In Sweden, Absolut Vodka has inked a new partnership with start-up Blue Ocean Closures to increase the use of biodegradable materials in its packaging....
“Magic” mushrooms take centerstage at Glastonbury music festival
In the United Kingdom, acoustic panels made from hemp and mycelium were used in the ceiling of a dance music tent at the recent ...
Beverage company and designer create Dirt Shoe that disintegrates in minutes
In New York, beverage company Yerba Madre and design studio Basura have partnered to create shoes out of dirt, organic fibers, and acacia gum...